Barclays has listed a list of global stocks for investors to consider buying before the end of the year, naming them “firm stock ideas with catalysts.” The bank’s list includes six stocks from the UK with an Overweight rating, with an average upside potential of 25%. Explaining why they maintained an overweight rating on UK equities, analysts at the bank said in an equity research note on October 11 that “hopes for a domestic recovery remain,” although they noted “cautious sentiment heading into the October budget.” . They wrote: “UK stocks remain under-owned overall and look very cheap. The FTSE 100 is short tech stocks, but the extension of gains currently favors value/defensive indexes.” Analysts also pointed out that domestic UK companies could benefit from “reduced uncertainty and better growth prospects,” which they said could lead to lower risk premiums in the medium term. Here are two stocks Barclays believes in, offering upside of more than 35%. SSP Group The biggest gainer was travel food and beverage operator SSP Group. Barclays described the stock as “attractive upside risk off valuation lows”. Shares are expected to rise 46.4% to £2.40 ($3.12) per share over the next 12 months. SSP’s shares are listed on the London Stock Exchange and trade in the United States as American Depositary Receipts (ADRs) under the symbol SSPPF-US. Year to date, shares are down about 30.4%. Barclays attributed its bullish stance to SSP’s “strong investment returns over the past two years, including the integration of past acquisitions.” “We believe continued action is being taken to drive profit growth (European margins have lagged due to contract renewals, German autobahn losses, industrial rail action and fundamental factors) and have hired a new European CEO to spearhead this More attention,” the analyst added. ConvaTec Medical products and technology company ConvaTec is another well-positioned company, according to Barclays, given the balanced growth across its business units. “We see upside potential to fiscal year guidance, especially given the delayed implementation of LCD and the buffer assumed in guidance for this,” analysts at the bank wrote. “Even in the worst-case scenario, management will We are also encouraged by the fact that we are confident of achieving 5-7% growth… and see continued underlying momentum across the businesses driven by strong launch activity.” ConvaTec’s shares are listed on the London Stock Exchange and in the United States as American depositary receipts trade under the symbol CNVVF-US. Shares have fallen nearly 6% so far this year. Barclays has a price target of £3.20 on the stock, giving it an upside potential of about 39.1%. —CNBC’s Michael Bloom contributed to this report.
Barclays names global ‘firm’ stock thinking for Q4 | Real Time Headlines
RELATED ARTICLES